Lettere minuti di lettura
E&P 2020, 44 (5-6) settembre-dicembre, p. 321-321
DOI: https://doi.org/doi.org/10.19191/EP20.5-6.P321.005
Glimepiride not inferior to linagliptin? No, even superior from a public health perspective
Glimepiride non inferiore al linagliptin? No, persino superiore dal punto di vista della sanità pubblica
In issue 42 of Diabetes Care released on December 2019, Matthew C. Riddle wrote the article “A Verdict for Glimepiride: Effective and Not Guilty of Cardiovascular Harm”.1
Riddle points out that the cardiovascular safety of sulfonylureas has been debated for nearly 50 years. He notes that, now, two convincing comparisons showed the former “neither an increase nor a decrease of risk with linagliptin versus placebo”, the second “the lack of excess cardiovascular risk with glimepiride versus linagliptin”. Taken together, these results “strongly suggests a neutral [cardiovascular] effect overall for glimepiride”.1
Correctly, he notes that, though glimepiride gave more hypoglycemia than linagliptin, “the frequency of hypoglycemia accompanying use of glimepiride […] cannot reliably be extrapolated to routine clinical practice... Accedi per continuare la lettura
Documenti scaricabili
| File | Dimensione | Download |
|---|---|---|
Full text 321-let3.pdf | 93 ㎅ | 1 |